These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26363507)

  • 1. Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.
    Nirogi R; Mohammed AR; Shinde AK; Bogaraju N; Gagginapalli SR; Ravella SR; Kota L; Bhyrapuneni G; Muddana NR; Benade V; Palacharla RC; Jayarajan P; Subramanian R; Goyal VK
    Eur J Med Chem; 2015 Oct; 103():289-301. PubMed ID: 26363507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.
    Brodney MA; Johnson DE; Sawant-Basak A; Coffman KJ; Drummond EM; Hudson EL; Fisher KE; Noguchi H; Waizumi N; McDowell LL; Papanikolaou A; Pettersen BA; Schmidt AW; Tseng E; Stutzman-Engwall K; Rubitski DM; Vanase-Frawley MA; Grimwood S
    J Med Chem; 2012 Nov; 55(21):9240-54. PubMed ID: 22974325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT
    Nirogi R; Mohammed AR; Shinde AK; Gagginapally SR; Kancharla DM; Ravella SR; Bogaraju N; Middekadi VR; Subramanian R; Palacharla RC; Benade V; Muddana N; Abraham R; Medapati RB; Thentu JB; Mekala VR; Petlu S; Lingavarapu BB; Yarra S; Kagita N; Goyal VK; Pandey SK; Jasti V
    J Med Chem; 2021 Aug; 64(15):10641-10665. PubMed ID: 34251799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT
    Nirogi R; Mohammed AR; Shinde AK; Gagginapally SR; Kancharla DM; Middekadi VR; Bogaraju N; Ravella SR; Singh P; Birangal SR; Subramanian R; Palacharla RC; Benade V; Muddana N; Jayarajan P
    J Med Chem; 2018 Jun; 61(11):4993-5008. PubMed ID: 29763304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.
    Yahiaoui S; Hamidouche K; Ballandonne C; Davis A; de Oliveira Santos JS; Freret T; Boulouard M; Rochais C; Dallemagne P
    Eur J Med Chem; 2016 Oct; 121():283-293. PubMed ID: 27266998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel non-sulfonamide 5-HT
    Vanda D; Soural M; Canale V; Chaumont-Dubel S; Satała G; Kos T; Funk P; Fülöpová V; Lemrová B; Koczurkiewicz P; Pękala E; Bojarski AJ; Popik P; Marin P; Zajdel P
    Eur J Med Chem; 2018 Jan; 144():716-729. PubMed ID: 29291439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment.
    Shen F; Smith JA; Chang R; Bourdet DL; Tsuruda PR; Obedencio GP; Beattie DT
    Neuropharmacology; 2011; 61(1-2):69-79. PubMed ID: 21392515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into serotonin 5-HT4 receptors : a novel therapeutic target for Alzheimer's disease?
    Maillet M; Robert SJ; Lezoualc'h F
    Curr Alzheimer Res; 2004 May; 1(2):79-85. PubMed ID: 15975071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
    Rochais C; Lecoutey C; Gaven F; Giannoni P; Hamidouche K; Hedou D; Dubost E; Genest D; Yahiaoui S; Freret T; Bouet V; Dauphin F; Sopkova de Oliveira Santos J; Ballandonne C; Corvaisier S; Malzert-Fréon A; Legay R; Boulouard M; Claeysen S; Dallemagne P
    J Med Chem; 2015 Apr; 58(7):3172-87. PubMed ID: 25793650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival.
    Cho S; Hu Y
    Exp Neurol; 2007 Jan; 203(1):274-8. PubMed ID: 16978609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist.
    Haydar SN; Ghiron C; Bettinetti L; Bothmann H; Comery TA; Dunlop J; La Rosa S; Micco I; Pollastrini M; Quinn J; Roncarati R; Scali C; Valacchi M; Varrone M; Zanaletti R
    Bioorg Med Chem; 2009 Jul; 17(14):5247-58. PubMed ID: 19515567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.
    Lecoutey C; Hedou D; Freret T; Giannoni P; Gaven F; Since M; Bouet V; Ballandonne C; Corvaisier S; Malzert Fréon A; Mignani S; Cresteil T; Boulouard M; Claeysen S; Rochais C; Dallemagne P
    Proc Natl Acad Sci U S A; 2014 Sep; 111(36):E3825-30. PubMed ID: 25157130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease.
    Russo O; Cachard-Chastel M; Rivière C; Giner M; Soulier JL; Berthouze M; Richard T; Monti JP; Sicsic S; Lezoualc'h F; Berque-Bestel I
    J Med Chem; 2009 Apr; 52(8):2214-25. PubMed ID: 19334715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease.
    Spencer JP; Brown JT; Richardson JC; Medhurst AD; Sehmi SS; Calver AR; Randall AD
    Neuroscience; 2004; 129(1):49-54. PubMed ID: 15489027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic 5-HT4 receptor activation decreases Aβ production and deposition in hAPP/PS1 mice.
    Tesseur I; Pimenova AA; Lo AC; Ciesielska M; Lichtenthaler SF; De Maeyer JH; Schuurkes JA; D'Hooge R; De Strooper B
    Neurobiol Aging; 2013 Jul; 34(7):1779-89. PubMed ID: 23474291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel multi target-directed ligands targeting 5-HT
    Lanthier C; Payan H; Liparulo I; Hatat B; Lecoutey C; Since M; Davis A; Bergamini C; Claeysen S; Dallemagne P; Bolognesi ML; Rochais C
    Eur J Med Chem; 2019 Nov; 182():111596. PubMed ID: 31419776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Molecular Basis of 5-HT
    Castro-Alvarez A; Chávez-Ángel E; Nelson R
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
    Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
    J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a series of benzoxazoles as potent 5-HT6 ligands.
    Liu KG; Lo JR; Comery TA; Zhang GM; Zhang JY; Kowal DM; Smith DL; Di L; Kerns EH; Schechter LE; Robichaud AJ
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1115-7. PubMed ID: 19152787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats.
    Boast C; Bartolomeo AC; Morris H; Moyer JA
    Neurobiol Learn Mem; 1999 May; 71(3):259-71. PubMed ID: 10196105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.